See more : Brookfield Renewable Corporation (BEPC.TO) Income Statement Analysis – Financial Results
Complete financial analysis of InnoCan Pharma Corporation (INNPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InnoCan Pharma Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- PostNL N.V. (PNL.AS) Income Statement Analysis – Financial Results
- Freetech Road Recycling Technology (Holdings) Limited (6888.HK) Income Statement Analysis – Financial Results
- Nan Juen International Co., Ltd. (6584.TWO) Income Statement Analysis – Financial Results
- Star Delta Transformers Limited (STARDELTA.BO) Income Statement Analysis – Financial Results
- CAI International, Inc. (CAI) Income Statement Analysis – Financial Results
InnoCan Pharma Corporation (INNPF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://innocanpharma.com
About InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 13.66M | 2.56M | 196.00K | 8.00K | 0.00 | 0.00 |
| Cost of Revenue | 1.68M | 452.00K | 75.00K | 5.00K | 23.53K | 0.00 |
| Gross Profit | 11.98M | 2.11M | 121.00K | 3.00K | -23.53K | 0.00 |
| Gross Profit Ratio | 87.71% | 82.34% | 61.73% | 37.50% | 0.00% | 0.00% |
| Research & Development | 1.80M | 1.53M | 1.40M | 1.37M | 368.00K | 534.00K |
| General & Administrative | 3.08M | 3.98M | 3.71M | 2.90M | 2.44M | 593.00K |
| Selling & Marketing | 10.91M | 2.86M | 2.50M | 337.00K | 194.00K | 39.00K |
| SG&A | 13.99M | 6.85M | 6.20M | 3.24M | 2.63M | 632.00K |
| Other Expenses | -7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.37M | 7.60M | 4.73M | 3.00M | 1.17M |
| Cost & Expenses | 9.85M | 8.83M | 7.68M | 4.73M | 3.00M | 1.17M |
| Interest Income | 23.42K | 21.00K | 13.00K | 8.00K | 40.00K | 0.00 |
| Interest Expense | 0.00 | 2.00K | 13.00K | 5.23M | 334.00K | 26.00K |
| Depreciation & Amortization | 33.61K | 33.61K | 42.62K | 42.11K | 23.53K | 2.00M |
| EBITDA | -3.77M | -3.70M | -7.44M | -4.69M | -2.98M | 0.00 |
| EBITDA Ratio | -27.60% | -242.67% | -3,794.39% | -58,562.50% | 0.00% | 0.00% |
| Operating Income | 3.80M | -6.27M | -7.48M | -4.73M | -3.00M | -1.17M |
| Operating Income Ratio | 27.85% | -244.86% | -3,816.33% | -59,062.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.84M | 2.38M | -2.61M | -5.23M | -334.00K | 806.86K |
| Income Before Tax | -4.03M | -3.89M | -10.09M | -9.95M | -3.34M | -1.19M |
| Income Before Tax Ratio | -29.54% | -151.93% | -5,148.47% | -124,412.50% | 0.00% | 0.00% |
| Income Tax Expense | 214.00K | 1.00K | -31.00K | -166.30K | -148.86K | -161.14K |
| Net Income | -4.70M | -3.76M | -10.05M | -9.95M | -3.34M | -1.19M |
| Net Income Ratio | -34.41% | -147.09% | -5,126.02% | -124,412.50% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 257.01M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
| Weighted Avg Shares Out (Dil) | 257.00M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Herzliya, Israel and Calgary, Alberta, October 21, 2024 – PRISM MediaWire – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it...
Innocan Pharma to Present at the 2024 ThinkEquity Conference
HERZLIYA, Israel and CALGARY, Alberta, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will...
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (the “Company”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased...
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science,...
Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), today announced that it has closed its previously announced private placement of the Company's common shares...
Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 8, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), today announced that it has entered into securities purchase agreements for a private placement of the...
Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that a new patent application has been filed for Innocan's CBD Delivery...
Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 24, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), hereby announces the filing by Ramot of a new patent application for a unique Cannabinoids exosome...
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome...
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 27, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") reports today, that since January 1st, 2021, it has received proceeds of approximately CAD $8.2M as...
Source: https://incomestatements.info
Category: Stock Reports